|Publication number||US20050106210 A1|
|Application number||US 10/989,946|
|Publication date||May 19, 2005|
|Filing date||Nov 16, 2004|
|Priority date||Apr 19, 1995|
|Also published as||CA2231727A1, CA2231727C, DE69636351D1, DE69636351T2, DE69636351T3, DE69637302D1, DE69637302T2, EP1019107A1, EP1019107B1, EP1019107B2, EP1500406A2, EP1500406A3, EP1500407A2, EP1500407A3, EP1500407B1, EP1559439A1, EP1559439B1, EP1647287A2, EP1647287A3, EP2082753A2, EP2082753A3, US5837313, US6358556, US20020071902, WO1997010011A1|
|Publication number||10989946, 989946, US 2005/0106210 A1, US 2005/106210 A1, US 20050106210 A1, US 20050106210A1, US 2005106210 A1, US 2005106210A1, US-A1-20050106210, US-A1-2005106210, US2005/0106210A1, US2005/106210A1, US20050106210 A1, US20050106210A1, US2005106210 A1, US2005106210A1|
|Inventors||Ni Ding, Michael Helmus|
|Original Assignee||Boston Scientific Scimed, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (99), Referenced by (25), Classifications (43), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The present application is a Continuation-In-Part of copending application Ser. No. 08/526,273, filed Sep. 11, 1995, and a Continuation-In-Part of copending application Ser. No. 08/424,884, filed Apr. 19, 1995, all portions of the parent applications not contained in this application being deemed incorporated by reference for any purpose. Cross-reference is also made to application Ser. No. 08/______, entitled “DRUG RELEASE STENT COATING AND PROCESS”, filed of even date and of common inventorship and assignee, that is also a Continuation-In-Part of both above-referenced patent applications. Any portion of that application that is not contained herein is also deemed to be incorporated by reference for any purpose.
II. Field of the Invention
The present invention relates generally to therapeutic expandable stent prosthesis for implantation in body lumens, e.g., vascular implantation and, more particularly, to a process for providing biostable elastomeric coatings on such stents which incorporate biologically active species having controlled release characteristics directly in the coating structure.
II. Related Art
In surgical or other related invasive medicinal procedures, the insertion and expansion of stent devices in blood vessels, urinary tracts or other difficult to access places for the purpose of preventing restenosis, providing vessel or lumen wall support or reinforcement and for other therapeutic or restorative functions has become a common form of long-term treatment. Typically, such prosthesis are applied to a location of interest utilizing a vascular catheter, or similar transluminal device, to carry the stent to the location of interest where it is thereafter released to expand or be expanded in situ. These devices are generally designed as permanent implants which may become incorporated in the vascular or other tissue which they contact at implantation.
One type of self-expanding stent has a flexible tubular body formed of several individual flexible thread elements each of which extends in a helix configuration with the centerline of the body serving as a common axis. The elements are wound in a common direction, but are displaced axially relative to each other and meet, under crossing a like number of elements also so axially displaced, but having the opposite direction of winding. This configuration provides a resilient braided tubular structure which assumes stable dimensions upon relaxation. Axial tension produces elongation and corresponding diameter contraction that allows the stent to be mounted on a catheter device and conveyed through the vascular system as a narrow elongated device. Once tension is relaxed in situ, the device at least substantially reverts to its original shape. Prosthesis of the class including a braided flexible tubular body are illustrated and described in U.S. Pat. Nos. 4,655,771 and 4,954,126 to Wallsten and 5,061,275 to Wallsten et al.
Implanted stents have also been used to carry medicinal agents, such as thrombolytic agents. U.S. Pat. No. 5,163,952 to Froix discloses a thermal memoried expanding plastic stent device which can be formulated to carry a medicinal agent by utilizing the material of the stent itself as an inert polymeric drug carrier. Pinchuk, in U.S. Pat. No. 5,092,877, discloses a stent of a polymeric material which may be employed with a coating associated with the delivery of drugs. Other patents which are directed to devices of the class utilizing bio-degradable or bio-sorbable polymers include Tang et al, U.S. Pat. No. 4,916,193, and MacGregor, U.S. Pat. No. 4,994,071. Sahatjian in U.S. Pat. No. 5,304,121, discloses a coating applied to a stent consisting of a hydrogel polymer and a preselected drug; possible drugs include cell growth inhibitors and heparin. A further method of making a coated intravascular stent carrying a therapeutic material in which a polymer coating is dissolved in a solvent and the therapeutic material dispersed in the solvent and the solvent thereafter evaporated is described in Berg et al, U.S. Pat. No. 5,464,650, issued Nov. 5, 1995 and corresponding to European patent application 0 623 354 A1 published 09 Nov. 1994.
An article by Michael N. Helmus (a co-inventor of the present invention) entitled “Medical Device Design—A Systems Approach: Central Venous Catheters”, 22nd International Society for the Advancement of Material and Process Engineering Technical Conference (1990) relates to polymer/drug/membrane systems for releasing heparin. Those polymer/ drug/membrane systems require two distinct layers to function.
The above cross-referenced grandparent application supplies an approach that provides long-term drug release, i.e., over a period of days or even months, incorporated in a controlled-release system. The parent application and present invention provide a process for coating such stents including techniques that enable the initial burst effect of drug elation to be controlled and the drug release kinetic profile associated with long-term therapeutic effect to be modified.
Metal stents of like thickness and weave generally have better mechanical properties than polymeric stents. Metallic vascular stents braided of even relatively fine metal filament can provide a large amount of strength to resist inwardly directed circumferential pressure in blood vessels. In order for a polymer material to provide comparable strength characteristics, a much thicker-walled structure or heavier, denser filament weave is required. This, in turn, reduces the cross-sectional area available for flow through the stent and/or reduces the relative amount of open space available in the structure. In addition, when applicable, it is usually more difficult to load and deliver polymeric stents using vascular catheter delivery systems.
It will be noted, however, that while certain types of stents such as braided metal stents may be superior to others for some applications, the process of the present invention is not limited in that respect and may be used to coat a wide variety of devices. The present invention also applies, for example, to the class of stents that are not self-expanding including those which can be expanded, for instance, with a balloon. Polymeric stents, of all kinds can be coated using the process. Thus, regardless of particular detailed embodiments the use of the invention is not considered or intended to be limited with respect either to stent design or materials of construction. Further, the present invention may be utilized with other types of implant prostheses.
Accordingly, it is a primary object of the present invention to provide a coating process for coating a stent to be used as a deployed stent prosthesis, the coating being capable of long-term delivery of biologically active materials.
Another object of the invention is to provide a process for coating a stent prosthesis using a biostable hydrophobic elastomer in which biologically active species are incorporated within a cured coating.
Still another object of the present invention is to provide a multi-layer coating in which the percentage of active material can vary from layer to layer.
A further object of the present invention is to control or modify aspects of the timed or time variable drug delivery from a stent coating by controlling average particle size in the biologically active species.
Other objects and advantages of the present invention will become apparent to those skilled in the art upon familiarization with the specification and appended claims.
The present invention provides processes for producing a relatively thin layer of biostable elastomeric material in which an amount of biologically active material is dispersed as a coating on the surfaces of a deployable stent prosthesis. The preferred stent to be coated is a self-expanding, open-ended tubular stent prosthesis. Although other materials, including polymer materials, can be used, in the preferred embodiment, the tubular body is formed of an open braid of fine single or polyfilament metal wire which flexes without collapsing and readily axially deforms to an elongate shape for transluminal insertion via a vascular catheter. The stent resiliently attempts to resume predetermined stable dimensions upon relaxation in situ.
The coating is preferably applied as a mixture, solution or suspension of polymeric material and finely divided biologically active species dispersed in an organic vehicle or a solution or partial solution of such species in a solvent or vehicle for the polymer and/or biologically active species. For the purpose of this application, the term “finally divided” means any type or size of included material from dissolved molecules through suspensions, colloids and particulate mixtures. The active material is dispersed in a carrier material which may be the polymer, a solvent, or both. The coating is preferably applied as a plurality of relatively thin layers sequentially applied in relatively rapid sequence and is preferably applied with the stent in a radially expanded state. In some applications the coating may further be characterized as a composite initial tie coat or undercoat and a composite topcoat. The coating thickness ratio of the topcoat to the undercoat may vary with the desired effect and/or the elution system. Typically these are of different formulations.
The coating may be applied by dipping or spraying using evaporative solvent materials of relatively high vapor pressure to produce the desired viscosity and quickly establish coating layer thicknesses. The preferred process is predicated on reciprocally spray coating a rotating radially expanded stent employing an air brush device. The coating process enables the material to adherently conform to and cover the entire surface of the filaments of the open structure of the stent but in a manner such that the open lattice nature of the structure of the braid or other pattern is preserved in the coated device.
The coating is exposed to room temperature ventilation for a predetermined time (possibly one hour or more) for solvent vehicle evaporation. Thereafter the polymeric precuser material is cured at room temperature or elevated temperatures or the solvent evaporated away from the dissolved polymer as the case may be. Curing is defined as the process of converting the elastomeric or polymeric material into the finished or useful state by the application of heat and/or chemical agents which include physical-chemical charges. Where, for example, polyurethane thermoplastic elastomers are used, solvent evaporation can occur at room temperature rendering the polymeric material useful for controlled drug release without further curing. Non-limiting examples of curing according to this definition include the application of heat and/or chemical agents and the evaporation of solvent which may induce physical and/or chemical changes.
The ventilation time and temperature for cure are determined by the particular polymer involved and particular drugs used. For example, silicone or polysiloxane materials (such as polydimethylsiloxane) have been used successfully. These materials are applied as pre-polymer in the coating composition and must thereafter be cured. The preferred species have a relatively low cure temperatures and are known as a room temperature vulcanizable (RTV) materials. Some polydimethylsiloxane materials can be cured, for example, by exposure to air at about 90° C. for a period of time such as 16 hours. A curing step may be implemented both after application of a certain number of lower undercoat layers and the topcoat layers or a single curing step used after coating is completed.
The coated stents may thereafter be subjected to a postcure sterilization process which includes an inert gas plasma treatment, and then exposure to gamma radiation, electron beam, ethylene oxide (ETO) or steam sterilization may also be employed.
In the plasma treatment, unconstrained coated stents are placed in a reactor chamber and the system is purged with nitrogen and a vacuum applied to about 20-50 mTorr. Thereafter, inert gas (argon, helium or mixture of them) is admitted to the reaction chamber for the plasma treatment. A highly preferred method of operation consists of using argon gas, operating at a power range from 200 to 400 watts, a flow rate of 150-650 standard ml per minute, which is equivalent to about 100-450 mTorr, and an exposure time from 30 seconds to about 5 minutes. The stents can be removed immediately after the plasma treatment or remain in the argon atmosphere for an additional period of time, typically five minutes.
After the argon plasma pretreatment, the coated and cured stents are subjected to gamma radiation sterilization nominally at 2.5-3.5 Mrad. The stents enjoy full resiliency after radiation whether exposed in a constrained or non-constrained status. It has been found that constrained stents subjected to gamma sterilization without utilizing the argon plasma pretreatment lose resiliency and do not recover at a sufficient or appropriate rate.
The elastomeric material that forms a major constituent of the stent coating should possess certain properties. It is preferably a suitable hydrophobic biostable elastomeric material which does not degrade and which minimizes tissue rejection and tissue inflammation and one which will undergo encapsulation by tissue adjacent to the stent implantation site. Polymers suitable for such coatings include silicones (e.g., polysiloxanes and substituted polysiloxanes), polyurethanes (including polycarbonate urethanes), thermoplastic elastomers in general, ethylene vinyl acetate copolymers, polyolefin elastomers, EPDM rubbers and polyamide elastomers. The above-referenced materials are considered hydrophobic with respect to the contemplated environment of the invention.
Agents suitable for incorporation-include antithrobotics, anticoagulants, antiplatelet agents, thrombolytics, antiproliferatives, antinflammatories, agents that inhibit hyperplasia and in particular restenosis, smooth muscle cell inhibitors, antibiotics growth factors, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters and drugs that may enhance the formation of healthy neointimal tissue, including endothelial cell regeneration. The positive action may come from inhibiting particular cells (e.g., smooth muscle cells) or tissue formation (e.g., fibromuscular tissue) while encouraging different cell migration (e.g., endothelium) and tissue formation (neointimal tissue).
The preferred materials for fabricating the braided stent include stainless steel, tantalum, titanium alloys including nitinol (a nickel titanium, thermomemoried alloy material), and certain cobalt alloys including cobalt-chromium-nickel alloys such as Elgiloy® and Phynox®. Further details concerning the fabrication and details of other aspects of the stents themselves, may be gleaned from the above referenced U.S. Pat. Nos. 4,655,771 and 4,954,126 to Wallsten and 5,061,275 to Wallsten et al. To the extent additional information contained in the above-referenced patents is necessary for an understanding of the present invention, they are deemed incorporated by reference herein.
Various combinations of polymer coating materials can be coordinated with biologically active species of interest to produce desired effects when coated on stents to be implanted in accordance with the invention. Loadings of therapeutic materials may vary. The mechanism of incorporation of the biologically active species into the surface coating, and egress mechanism depend both on the nature of the surface coating polymer and the material to be incorporated. The mechanism of release also depends on the mode of incorporation. The material may elute via interparticle paths or be administered via transport or diffusion through the encapsulating material itself.
For the purposes of this specification, “elution” is defined as any-process of release that involves extraction or release by direct contact of the material with bodily fluids through the interparticle paths connected with the exterior of the coating. “Transport” or “diffusion” are defined to include a mechanism of release in which a material released traverses through another material.
The desired release rate profile can be tailored by varying the coating thickness, the radial distribution (layer to layer) of bioactive materials, the mixing method, the amount of bioactive material, the combination of different matrix polymer materials at different layers, and the crosslink density of the polymeric material. The crosslink density is related to the amount of crosslinking which takes place and also the relative tightness of the matrix created by the particular crosslinking agent used. This, during the curing process, determines the amount of crosslinking and so the crosslink density of the polymer material. For bioactive materials released from the crosslinked matrix, such as heparin, a crosslink structure of greater density will increase release time and reduce burst effect.
Additionally, with eluting materials such as heparin, release kinetics, particularly initial drug release rate, can be affected by varying the average dispersed particle size. The observed initial release rate or burst effect may be substantially reduced by using smaller particles, particularly if the particle size is controlled to be less than about 15 microns and the effect is even more significant in the particle size range of ≦10 microns, especially when the coating thickness is not more than about 50 μm and drug loading is about 25-45 weight percent.
It will also be appreciated that an unmedicated silicone thin top layer provides an advantage over drug containing top coat. Its surface has a limited porosity and is generally smooth, which may be less thrombogeneous and may reduce the chance to develop calcification, which occurs most often on the porous surface.
In the drawings, wherein like numerals designate like parts throughout the same:
According to the present invention, the stent coatings incorporating biologically active materials for timed delivery in situ in a body lumen of interest are preferably sprayed in many thin layers from prepared coating solutions or suspensions. The steps of the process are illustrated generally in
General Preparation of Heparin Coating Composition
Silicone was obtained as a polymer precursor in solvent (xylene) mixture. For example, a 35% solid silicone weight content in xylene was procured from Applied Silicone, Part #40,000. First, the silicone-xylene mixture was weighed. The solid silicone content was determined according to the vendor's analysis. Precalculated amounts of finely divided heparin (2-6 microns) were added into the silicone, then tetrahydrofuron (THF) HPCL grade (Aldrich or EM) was added. For a 37.5% heparin coating, for example: Wsilicone=5 g; solid percent=35%; Whep=5×0.35×0.375/(0.625)=1.05 g. The amount of THF needed (44 ml) in the coating solution was calculated by using the equation Wsilicone solid/VTHF=0.04 for a 37.5% heparin coating solution). Finally, the manufacturer crosslinker solution was added by using Pasteur P-pipet. The amount of crosslinker added was formed to effect the release rate profile. Typically, five drops of crosslinker solution were added for each five grams of silicone-xylene mixture. The crosslinker may be any suitable and compatible agent including platinum and peroxide based materials. The solution was stirred by using the stirring rod until the suspension was homogenous and milk-like. The coating solution was then transferred into a paint jar in condition for application by air brush.
General Preparation of Dexamethasone Coating Composition
Silicone (35% solution as above) was weighed into a beaker on a Metler balance. The weight of dexamethasone free alcohol or acetate form was calculated by silicone weight multiplied by 0.35 and the desired percentage of dexamethasone (1 to 40%) and the required amount was then weighed. Example: Wsilicone=5 g; for a 10% dexamethasone coating, Wdex=5×0.35×0.1/0.9=0.194 g and THF needed in the coating solution calculated. Wsilicone solid/VTHF=0.06 for a 10% dexamethasone coating solution. Example: Wsilicone=5 g; VTHF=5×0.35/0.06≈29 ml. The dexamethasone was weighed in a beaker on an analytical balance and half the total amount of THF was added. The solution was stirred well to ensure full dissolution of the dexamethasone. The stirred DEX-THF solution was then transferred to the silicone container. The beaker was washed with the remaining THF and this was transferred to the silicone container. The crosslinker was added by using a Pasteur pipet. Typically, five drops of crosslinker were used for five grams of silicone.
The application of the coating material to the stent was quite similar for all of the materials and the same for the heparin and dexamethasone suspensions prepared as in the above Examples. The suspension to be applied was transferred to an application device, typically a paint jar attached to an air brush, such as a Badger Model 150, supplied with a source of pressurized air through a regulator (Norgren, 0-160 psi). Once the brush hose was attached to the source of compressed air downstream of the regulator, the air was applied. The pressure was adjusted to approximately 15-25 psi and the nozzle condition checked by depressing the trigger.
Any appropriate method can be used to secure the stent for spraying and rotating fixtures were utilized successfully in the laboratory. Both ends of the relaxed stent were fastened to the fixture by two resilient retainers, commonly alligator clips, with the distance between the clips adjusted so that the stent remained in a relaxed, unstretched condition. The rotor was then energized and the spin speed adjusted to the desired coating speed, nominally about 40 rpm.
With the stent rotating in a substantially horizontal plane, the spray nozzle was adjusted so that the distance from the nozzle to the stent was about 2-4 inches and the composition was sprayed substantially horizontally with the brush being directed along the stent from the distal end of the stent to the proximal end and then from the proximal end to the distal end in a sweeping motion at a speed such that one spray cycle occurred in about three stent rotations. Typically a pause of less than one minute, normally about one-half minute, elapsed between layers. Of course, the number of coating layers did and will vary with the particular application. For example, for a coating level of 3-4 mg of heparin per cm2 of projected area, 20 cycles of coating application are required and about 30 ml of solution will be consumed for a 3.5 mm diameter by 14.5 cm long stent.
The rotation speed of the motor, of course, can be adjusted as can the viscosity of the composition and the flow rate of the spray nozzle as desired to modify the layered structure. Generally, with the above mixes, the best results have been obtained at rotational speeds in the range of 30-50 rpm and with a spray nozzle flow rate in the range of 4-10 ml of coating composition per minute, depending on the stent size. It is contemplated that a more sophisticated, computer-controlled coating apparatus will successfully automate the process demonstrated as feasible in the laboratory.
Several applied layers make up what is called the tie layer as at 18 and thereafter additional upper layers, which may be of a different composition with respect to bioactive material, the matrix polymeric materials and crosslinking agent, for example, are applied as the top layer as at 20. The application of the top layer follows the same coating procedure as the tie layer with the number and thickness of layers being optional. Of course, the thickness of any layer can be adjusted by modifying the speed of rotation of the stent and the spraying conditions. Generally, the total coating thickness is controlled by the number of spraying cycles or thin coats which make up the total coat.
As shown at 22 in
Stents coated and cured in the manner described need to be sterilized prior to packaging for future implantation. For sterilization, gamma radiation is a preferred method particularly for heparin containing coatings; however, it has been found that stents coated and cured according to the process of the invention subjected to gamma sterilization may be too slow to recover their original posture when delivered to a vascular or other lumen site using a catheter unless a pretreatment step as at 24 is first applied to the coated, cured stent.
The pretreatment step involves an argon plasma treatment of the coated, cured stents in the unconstrained configuration. In accordance with this procedure, the stents are placed in a chamber of a plasma surface treatment system such as a Plasma Science 350 (Himont/Plasma Science, Foster City, Calif.). The system is equipped with a reactor chamber and RF solid-state generator operating at 13.56 mHz and from 0-500 watts power output and being equipped with a microprocessor controlled system and a complete vacuum pump package. The reaction chamber contains an unimpeded work volume of 16.75 inches (42.55 cm) by 13.5 inches (34.3 cm) by 17.5 inches (44.45 cm) in depth.
In the plasma process, unconstrained coated stents are placed in a reactor chamber and the system is purged with nitrogen and a vacuum applied to 20-50 mTorr. Thereafter, inert gas (argon, helium or mixture of them) is admitted to the reaction chamber for the plasma treatment. A highly preferred method of operation consists of using argon gas, operating at a power range from 200 to 400 watts, a flow rate of 150-650 standard ml per minute, which is equivalent to 100-450 mTorr, and an exposure time from 30 seconds to about 5 minutes. The stents can be removed immediately after the plasma treatment or remain in the argon atmosphere for an additional period of time, typically five minutes.
After this, as shown at 26, the stents are exposed to gamma sterilization at 2.5-3.5 Mrad. The radiation may be carried out with the stent in either the radially non-constrained status—or in the radially constrained status.
With respect to the anticoagulant material heparin, the percentage in the tie layer is nominally from about 20-50% and that of the top layer from about 0-30% active material. The coating thickness ratio of the top layer to the tie layer varies from about 1:10 to 1:2 and is preferably in the range of from about 1:6 to 1:3.
Suppressing the burst effect also enables a reduction in the drug loading or in other words, allows a reduction in the coating thickness, since the physician will give a bolus injection of antiplatelet/anticoagulation drugs to the patient during the stenting process. As a result, the drug imbedded in the stent can be fully used without waste. Tailoring the first day release, but maximizing second day and third day release at the thinnest possible coating configuration will reduce the acute or subcute thrombosis.
The effect of average particle size is depicted in the
In addition, as shown in the photomicrographs of
Accordingly, it has been found that the average particle size should generally be controlled below about 15 μm to reduce the burst effect and preferably should be ≦ about 10 μm for best results. The 4-6 μm size worked quite successfully in the laboratory. However, it should be noted that larger particle size can also be advantageously used, for instance, when the drug load is low, such as below 25 weight percent. Elution kinetics can be adjusted by a combination of changing the particle size and changing the load or concentration of the dispersed drug material.
What is apparent from the data gathered to date, however, is that the process of the present invention enables the drug elution kinetics to be modified to meet the needs of the particular stent application. In a similar manner, stent coatings can be prepared using a combination of two or more drugs and the drug release sequence and rate controlled. For example, antiproliferation drugs may be combined in the undercoat and anti-thrombotic drugs in the topcoat layer. In this manner, the anti-thrombotic drugs, for example, heparin, will elute first followed by antiproliferation drugs, e.g. dexamethasone, to better enable safe encapsulation of the implanted stent.
The heparin concentration measurement were made utilizing a standard curve prepared by complexing azure A dye with dilute solutions of heparin. Sixteen standards were used to compile the standard curve in a well-known manner.
For the elution test, the stents were immersed in a phosphate buffer solution at pH 7.4 in an incubator at approximately 37° C. Periodic samplings of the solution were processed to determine the amount of heparin eluted. After each sampling, each stent was placed in heparin-free buffer solution.
As stated above, while the allowable loading of the elastomeric material with heparin may vary, in the case of silicone materials heparin may exceed 60% of the total weight of the layer. However, the loading generally most advantageously used is in the range from about 10% to 45% of the total weight of the layer. In the case of dexamethasone, the loading may be as high as 50% or more of the total weight of the layer but is preferably in the range of about 0.4% to 45%.
It will be appreciated that the mechanism of incorporation of the biologically active species into a thin surface coating structure applicable to a metal stent is an important aspect of the present invention. The need for relatively thick-walled polymer elution stents or any membrane overlayers associated with many prior drug elution devices is obviated, as is the need for utilizing biodegradable or reabsorbable vehicles for carrying the biologically active species. The technique clearly enables long-term delivery and minimizes interference with the independent mechanical or therapeutic benefits of the stent itself.
Coating materials are designed with a particular coating technique, coating/drug combination and drug infusion mechanism in mind. Consideration of the particular form and mechanism of release of the biologically active species in the coating allow the technique to produce superior results. In this manner, delivery of the biologically active species from the coating structure can be tailored to accommodate a variety of applications.
Whereas the above examples depict-coatings having two different drug loadings or percentages of biologically active material to be released, this is by no means limiting with respect to the invention and it is contemplated that any number of layers and combinations of loadings can be employed to achieve a desired release profile. For example, gradual grading and change in the loading of the layers can be utilized in which, for example, higher loadings are used in the inner layers. Also layers can be used which have no drug loadings at all. For example, a pulsatile heparin release system may be achieved by a coating in which alternate layers containing heparin are sandwiched between unloaded layers of silicone or other materials for a portion of the coating. In other words, the invention allows untold numbers of combinations which result in a great deal of flexibility with respect to controlling the release of biologically active materials with regard to an implanted stent. Each applied layer is typically from approximately 0.5 microns to 15 microns in thickness. The total number of sprayed layers, of course, can vary widely, from less than 10 to more than 50 layers; commonly, 20 to 40 layers are included. The total thickness of the coating can also vary widely, but can generally be from about 10 to 200 microns.
Whereas the polymer of the coating may be any compatible biostable elastomeric material capable of being adhered to the stent material as a thin layer, hydrophobic materials are preferred because it has been found that the release of the biologically active species can generally be more predictably controlled with such materials. Preferred materials include silicone rubber elastomers and biostable polyurethanes specifically.
This invention has been described herein in considerable detail in order to comply with the Patent Statutes and to provide those skilled in the art with the information needed to apply the novel principles and to construct and use embodiments of the example as required. However, it is to be understood that the invention can be carried out by specifically different devices and that various modifications can be accomplished without departing from the scope of the invention itself.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3168565 *||Nov 20, 1959||Feb 2, 1965||Richardson Merrell Inc||Trifluoromethyl derivatives of amino triarylethanols, -ethanes, and -ethylenes|
|US3634517 *||Aug 19, 1968||Jan 11, 1972||Richardson Merrell Inc||Triarylalkenones|
|US3932627 *||Feb 4, 1974||Jan 13, 1976||Rescue Products, Inc.||Siver-heparin-allantoin complex|
|US3940422 *||Jan 17, 1974||Feb 24, 1976||Kissei Yakuhin Kogyo Kabushiki Kaisha||Aromatic carboxylic amide derivatives|
|US4070484 *||Dec 21, 1976||Jan 24, 1978||Kissei Pharmaceutical Co., Ltd.||Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same|
|US4133814 *||Sep 17, 1976||Jan 9, 1979||Eli Lilly And Company||2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents|
|US4310523 *||Oct 10, 1980||Jan 12, 1982||Schering Aktiengesellschaft||Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate|
|US4315028 *||Sep 18, 1979||Feb 9, 1982||Scheinberg Israel H||Method of treatment of rheumatoid arthritis|
|US4317915 *||Jan 14, 1980||Mar 2, 1982||Hoffmann-La Roche Inc.||Novel thiophene derivatives|
|US4428963 *||Mar 10, 1983||Jan 31, 1984||Hoffmann-La Roche Inc.||Novel thiophene derivatives|
|US4491574 *||Mar 2, 1983||Jan 1, 1985||Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University||Reduction of high dose aspirin toxicity by dietary vitamin A|
|US4577636 *||Jan 27, 1984||Mar 25, 1986||The Beth Israel Hospital Association||Method for diagnosis of atherosclerosis|
|US4732763 *||Sep 28, 1984||Mar 22, 1988||Stolle Research And Development Corporation||Active/passive immunization of the internal female reproductive organs|
|US4733665 *||Nov 7, 1985||Mar 29, 1988||Expandable Grafts Partnership||Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft|
|US4894231 *||Jul 28, 1987||Jan 16, 1990||Biomeasure, Inc.||Therapeutic agent delivery system|
|US4897255 *||Jun 19, 1987||Jan 30, 1990||Neorx Corporation||Metal radionuclide labeled proteins for diagnosis and therapy|
|US4900561 *||Jan 3, 1989||Feb 13, 1990||Zinpro Corporation||Copper complexes of alpha-amino acids that contain terminal amino groups, and their use as nutritional supplements|
|US4906452 *||Apr 28, 1988||Mar 6, 1990||Neorx Corporation||Trichothecene conjugates and methods of use|
|US4984594 *||Oct 27, 1989||Jan 15, 1991||Shell Oil Company||Vacuum method for removing soil contamination utilizing surface electrical heating|
|US4990158 *||May 10, 1989||Feb 5, 1991||United States Surgical Corporation||Synthetic semiabsorbable tubular prosthesis|
|US4990538 *||Aug 23, 1989||Feb 5, 1991||Harris Adrian L||Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs|
|US4994033 *||May 25, 1989||Feb 19, 1991||Schneider (Usa) Inc.||Intravascular drug delivery dilatation catheter|
|US4994071 *||May 22, 1989||Feb 19, 1991||Cordis Corporation||Bifurcating stent apparatus and method|
|US4994384 *||Oct 27, 1987||Feb 19, 1991||W. R. Grace & Co.-Conn.||Multiplying bovine embryos|
|US4996225 *||Oct 12, 1989||Feb 26, 1991||Farmos Group Ltd.||Tri-phenyl alkane derivatives and their oestrogenic, anti-oestrogenic and progestanic uses|
|US4997652 *||May 31, 1989||Mar 5, 1991||Visionex||Biodegradable ocular implants|
|US5082834 *||Sep 18, 1990||Jan 21, 1992||Sorensen John R J||Anti-inflammatory and anti-ulcer compounds and process|
|US5176617 *||Oct 21, 1991||Jan 5, 1993||Medical Innovative Technologies R & D Limited Partnership||Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct|
|US5180366 *||Oct 10, 1990||Jan 19, 1993||Woods W T||Apparatus and method for angioplasty and for preventing re-stenosis|
|US5180376 *||May 1, 1990||Jan 19, 1993||Cathco, Inc.||Non-buckling thin-walled sheath for the percutaneous insertion of intraluminal catheters|
|US5182317 *||Jun 17, 1991||Jan 26, 1993||Cardiopulmonics, Inc.||Multifunctional thrombo-resistant coatings and methods of manufacture|
|US5185260 *||Aug 29, 1991||Feb 9, 1993||The United States Of America As Represented By The United States Department Of Energy||Method for distinguishing normal and transformed cells using G1 kinase inhibitors|
|US5185408 *||Nov 18, 1991||Feb 9, 1993||Allied-Signal Inc.||Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides|
|US5188791 *||Apr 1, 1991||Feb 23, 1993||Savoie Refractaires||Concrete composition for the manufacture of moulds, mould and process for the manufacture of a mould|
|US5189046 *||Jun 4, 1991||Feb 23, 1993||Nova Pharmaceutical Corporation||Protein kinase C modulators|
|US5189212 *||Sep 7, 1990||Feb 23, 1993||University Of Georgia Research Foundation, Inc.||Triarylethylene carboxylic acids with estrogenic activity|
|US5280016 *||Sep 3, 1991||Jan 18, 1994||Glycomed Incorporated||Non-anticoagulant heparin derivatives|
|US5280040 *||Mar 11, 1993||Jan 18, 1994||Zymogenetics, Inc.||Methods for reducing bone loss using centchroman derivatives|
|US5280109 *||Jan 27, 1992||Jan 18, 1994||Ludwig Institute For Cancer Research||Isolated, large latent complexes of TGF-β2 and TGF-β3, and new binding protein for latent form TGF-β1, TGF-β2 and TGF-β3 LTBP-2|
|US5282785 *||Oct 5, 1992||Feb 1, 1994||Cortrak Medical, Inc.||Drug delivery apparatus and method|
|US5282823 *||Mar 19, 1992||Feb 1, 1994||Medtronic, Inc.||Intravascular radially expandable stent|
|US5283257 *||Jul 10, 1992||Feb 1, 1994||The Board Of Trustees Of The Leland Stanford Junior University||Method of treating hyperproliferative vascular disease|
|US5284763 *||Mar 4, 1992||Feb 8, 1994||Genentech, Inc.||Nucleic acid encoding TGF-β and its uses|
|US5284869 *||Dec 17, 1991||Feb 8, 1994||Emil Bisaccia||Photophoresis methods for treating atherosclerosis and for preventing restenosis following angioplasty|
|US5288711 *||Apr 28, 1992||Feb 22, 1994||American Home Products Corporation||Method of treating hyperproliferative vascular disease|
|US5288735 *||Jun 15, 1992||Feb 22, 1994||Trager Seymour F||Treatment of glaucoma|
|US5378475 *||Feb 21, 1991||Jan 3, 1995||University Of Kentucky Research Foundation||Sustained release drug delivery devices|
|US5380299 *||Aug 30, 1993||Jan 10, 1995||Med Institute, Inc.||Thrombolytic treated intravascular medical device|
|US5380716 *||Dec 28, 1992||Jan 10, 1995||Glycomed, Inc.||Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation|
|US5383928 *||Aug 19, 1993||Jan 24, 1995||Emory University||Stent sheath for local drug delivery|
|US5384332 *||May 11, 1994||Jan 24, 1995||Eli Lilly And Company||Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives|
|US5385935 *||Sep 7, 1993||Jan 31, 1995||Kissei Pharmaceutical Co., Ltd.||Method for the inhibition of restenosis associated with coronary intervention|
|US5387680 *||Aug 10, 1993||Feb 7, 1995||American Home Products Corporation||C-22 ring stabilized rapamycin derivatives|
|US5389670 *||Dec 21, 1993||Feb 14, 1995||Eli Lilly Company||Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder|
|US5391378 *||Feb 22, 1993||Feb 21, 1995||Elizabeth-Hata International, Inc.||Two-part medicinal tablet and method of manufacture|
|US5391557 *||Oct 15, 1993||Feb 21, 1995||Eli Lilly And Company||Methods for the treatment of peri-menopausal syndrome|
|US5393763 *||Jan 12, 1994||Feb 28, 1995||Eli Lilly And Company||Methods for inhibiting bone loss|
|US5393772 *||Nov 24, 1993||Feb 28, 1995||Boehringer Mannheim Pharmaceuticals Corporation||Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation|
|US5393785 *||Jul 14, 1992||Feb 28, 1995||Endorecherche, Inc.||Therapeutic antiestrogens|
|US5480888 *||Jan 14, 1993||Jan 2, 1996||Daiichi Pharmaceutical Co., Ltd.||Inhibitor for restenosis after percutaneous coronary arterioplasty|
|US5480903 *||Apr 17, 1994||Jan 2, 1996||Zymogenetics, Inc.||3,4-diarylchromans for inhibiting calmodulin activity|
|US5480904 *||Oct 28, 1993||Jan 2, 1996||Eli Lilly And Company||Methods for inhibiting uterine fibrosis|
|US5482851 *||Nov 5, 1993||Jan 9, 1996||Genentech, Inc.||Nucleic acid encoding TGF-β and its uses|
|US5482949 *||Mar 19, 1993||Jan 9, 1996||Eli Lilly And Company||Sulfonate derivatives of 3-aroylbenzo[b]thiophenes|
|US5482950 *||Oct 15, 1993||Jan 9, 1996||Eli Lilly And Company||Methods for lowering serum cholesterol|
|US5484795 *||Apr 21, 1995||Jan 16, 1996||Eli Lilly And Company||Naphthyl compounds, intermediates, processes, compositions, and method of inhibiting restenosis|
|US5484796 *||Apr 21, 1995||Jan 16, 1996||Eli Lilly And Company||Naphthyl compounds, intermediates, processes, compositions, and method of inhibiting aortal smooth muscle cell proliferation|
|US5484797 *||Apr 21, 1995||Jan 16, 1996||Eli Lilly And Company||Naphthly compounds, intermediates, processes, compositions, and method for inhibiting endometrosis|
|US5484798 *||Apr 19, 1995||Jan 16, 1996||Eli Lilly And Company||Benzothiopene compounds, compositions, and method of inhibiting restenosis|
|US5484808 *||Feb 9, 1995||Jan 16, 1996||Eli Lilly And Company||Methods of inhibiting cell-cell adhesion|
|US5486357 *||Oct 27, 1993||Jan 23, 1996||Cordis Corporation||Radiofrequency plasma biocompatibility treatment of inside surfaces|
|US5489587 *||Jan 20, 1995||Feb 6, 1996||Eli Lilly And Company||Benzofurans used to inhibit bone loss|
|US5491159 *||Aug 30, 1994||Feb 13, 1996||American Home Products Corporation||2-(3,5-di-tert-butyl-4-hydroxy-phenyl)-oxazoles as anti-atherosclerotic agents|
|US5491173 *||Jan 24, 1994||Feb 13, 1996||Orion-Yhtyma Oy||Tri-phenyl alkene derivatives and their preparation and use|
|US5492895 *||Feb 14, 1994||Feb 20, 1996||Corvas International, Inc.||Inhibitors of thrombosis|
|US5492921 *||Apr 19, 1995||Feb 20, 1996||Eli Lilly And Company||Benzothiophene compounds, compositions, and methods for inhibiting aortal smooth muscle proliferation|
|US5492922 *||Jun 6, 1995||Feb 20, 1996||Eli Lilly And Company||Benzothiophene compounds intermediate compositions and methods for inhibiting aortal smooth muscle proliferation|
|US5492926 *||Apr 14, 1995||Feb 20, 1996||Eli Lilly And Company||Methods for inhibiting vascular smooth muscle cell proliferation and restinosis|
|US5492927 *||Dec 21, 1993||Feb 20, 1996||Eli Lilly And Company||Non-peptide tachykinin receptor antagonists to treat allergy|
|US5493931 *||Feb 14, 1994||Feb 27, 1996||Grand Haven Stamped Products Company, Div. Of Jsj Corp.||Vehicle shifter|
|US5591224 *||Sep 15, 1994||Jan 7, 1997||Medtronic, Inc.||Bioelastomeric stent|
|US5591227 *||Apr 27, 1995||Jan 7, 1997||Medtronic, Inc.||Drug eluting stent|
|US5595722 *||Jun 7, 1995||Jan 21, 1997||Neorx Corporation||Method for identifying an agent which increases TGF-beta levels|
|US5597578 *||Apr 28, 1994||Jan 28, 1997||Oncogen||TGF-β protein compositions for inhibition of cell proliferation|
|US5599352 *||Sep 15, 1994||Feb 4, 1997||Medtronic, Inc.||Method of making a drug eluting stent|
|US5599844 *||Sep 15, 1995||Feb 4, 1997||Neorx Corporation||Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells|
|US5605696 *||Mar 30, 1995||Feb 25, 1997||Advanced Cardiovascular Systems, Inc.||Drug loaded polymeric material and method of manufacture|
|US5605700 *||Mar 25, 1993||Feb 25, 1997||Orion-Yhtyma Oy||Topical administration of toremifene and its metabolites|
|US5705477 *||Jul 5, 1994||Jan 6, 1998||The United States Of America As Represented By The Department Of Health And Human Services||Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use|
|US5705609 *||May 16, 1995||Jan 6, 1998||La Jolla Cancer Research Foundation||Decorin fragments inhibiting cell regulatory factors|
|US5716981 *||Jun 7, 1995||Feb 10, 1998||Angiogenesis Technologies, Inc.||Anti-angiogenic compositions and methods of use|
|US5863285 *||Jan 30, 1997||Jan 26, 1999||Cordis Corporation||Balloon catheter with radioactive means|
|US5873904 *||Feb 24, 1997||Feb 23, 1999||Cook Incorporated||Silver implantable medical device|
|US6013099 *||Apr 29, 1998||Jan 11, 2000||Medtronic, Inc.||Medical device for delivering a water-insoluble therapeutic salt or substance|
|US6168619 *||Oct 16, 1998||Jan 2, 2001||Quanam Medical Corporation||Intravascular stent having a coaxial polymer member and end sleeves|
|US6171609 *||Oct 23, 1995||Jan 9, 2001||Neorx Corporation||Therapeutic inhibitor of vascular smooth muscle cells|
|US6187370 *||Sep 16, 1999||Feb 13, 2001||Medtronic, Inc.||Medical device for delivering a therapeutic substance and method therefor|
|US6689159 *||May 1, 2003||Feb 10, 2004||Advanced Cardiovascular Systems, Inc.||Expandable stents and method for making same|
|US20030039675 *||Nov 27, 2001||Feb 27, 2003||Angiotech Pharmaceuticals, Inc.||Therapeutic inhibitor of vascular smooth muscle cells|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7648727||Aug 26, 2004||Jan 19, 2010||Advanced Cardiovascular Systems, Inc.||Methods for manufacturing a coated stent-balloon assembly|
|US7658758||Mar 2, 2005||Feb 9, 2010||Innovational Holdings, Llc||Method and apparatus for loading a beneficial agent into an expandable medical device|
|US7691401||May 17, 2005||Apr 6, 2010||Advanced Cardiovascular Systems, Inc.||Poly(butylmethacrylate) and rapamycin coated stent|
|US7713637||Mar 3, 2006||May 11, 2010||Advanced Cardiovascular Systems, Inc.||Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer|
|US7758636||Mar 14, 2005||Jul 20, 2010||Innovational Holdings Llc||Expandable medical device with openings for delivery of multiple beneficial agents|
|US7758881||Mar 24, 2005||Jul 20, 2010||Advanced Cardiovascular Systems, Inc.||Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device|
|US7775178||May 26, 2006||Aug 17, 2010||Advanced Cardiovascular Systems, Inc.||Stent coating apparatus and method|
|US7785647||Jul 25, 2005||Aug 31, 2010||Advanced Cardiovascular Systems, Inc.||Methods of providing antioxidants to a drug containing product|
|US7807211||May 27, 2004||Oct 5, 2010||Advanced Cardiovascular Systems, Inc.||Thermal treatment of an implantable medical device|
|US7854957||Jan 30, 2007||Dec 21, 2010||Innovational Holdings, Llc||Systems and methods for producing a medical device|
|US7862495||May 31, 2001||Jan 4, 2011||Advanced Cardiovascular Systems, Inc.||Radiation or drug delivery source with activity gradient to minimize edge effects|
|US7867547||Dec 19, 2005||Jan 11, 2011||Advanced Cardiovascular Systems, Inc.||Selectively coating luminal surfaces of stents|
|US7997226||Jan 30, 2007||Aug 16, 2011||Innovational Holdings Llc||Systems and methods for producing a medical device|
|US8011316||Jan 30, 2007||Sep 6, 2011||Innovational Holdings, Llc||Systems and methods for producing a medical device|
|US8029816||May 10, 2007||Oct 4, 2011||Abbott Cardiovascular Systems Inc.||Medical device coated with a coating containing elastin pentapeptide VGVPG|
|US8067025||Mar 20, 2007||Nov 29, 2011||Advanced Cardiovascular Systems, Inc.||Nitric oxide generating medical devices|
|US8147769 *||May 16, 2007||Apr 3, 2012||Abbott Cardiovascular Systems Inc.||Stent and delivery system with reduced chemical degradation|
|US8524166||Mar 12, 2012||Sep 3, 2013||Abbott Cardiovascular Systems Inc.||Stent and delivery system with reduced chemical degradation including a Chitooligosaccharide|
|US8709469||Jul 16, 2010||Apr 29, 2014||Abbott Cardiovascular Systems Inc.||Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device|
|US8932345||Feb 4, 2008||Jan 13, 2015||Cook Medical Technologies Llc||Medical device coatings for releasing a therapeutic agent at multiple rates|
|US9056155||May 29, 2007||Jun 16, 2015||Abbott Cardiovascular Systems Inc.||Coatings having an elastic primer layer|
|US20040098117 *||Sep 22, 2003||May 20, 2004||Hossainy Syed F.A.||Composite stent with regioselective material and a method of forming the same|
|US20040238978 *||Jun 18, 2004||Dec 2, 2004||Diaz Stephen Hunter||Method and apparatus for loading a benefical agent into an expandable medical device|
|US20050002986 *||Apr 21, 2004||Jan 6, 2005||Robert Falotico||Drug/drug delivery systems for the prevention and treatment of vascular disease|
|US20050287287 *||Jun 24, 2004||Dec 29, 2005||Parker Theodore L||Methods and systems for loading an implantable medical device with beneficial agent|
|U.S. Classification||424/423, 427/2.1, 623/1.42|
|International Classification||A61L31/00, A61L33/00, A61F, A61K9/00, A61L, A61F2/90, A61F2/82, A61F2/86, A61L27/22, A61F2/00, A61L31/10, A61L31/14, A61L31/16|
|Cooperative Classification||A61L33/0011, A61L2300/236, A61F2/90, A61L2300/602, A61F2250/0067, A61L31/10, A61L2420/02, A61L31/141, A61F2/86, A61L2300/406, A61F2/82, A61L31/16, A61F2210/0014, A61L2300/42, A61L2300/222, A61L2300/608, A61L2300/606, A61L2300/622, A61L27/227|
|European Classification||A61L27/22R, A61L31/10, A61L31/16, A61L33/00H2, A61L31/14B, A61F2/86, A61F2/90, A61F2/82|
|Oct 30, 2006||AS||Assignment|
Owner name: SCIMED LIFE SYSTEMS, INC., MINNESOTA
Free format text: MERGER;ASSIGNOR:BOSTON SCIENTIFIC SCIMED, INC.;REEL/FRAME:018454/0834
Effective date: 20050101
Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA
Free format text: CHANGE OF NAME;ASSIGNOR:SCHNEIDER (USA) INC.;REEL/FRAME:018454/0858
Effective date: 19990427
Owner name: BOSTON SCIENTIFIC SCIMED, INC., MINNESOTA
Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:018454/0866
Effective date: 20050101
|Jun 17, 2010||AS||Assignment|
Owner name: SCHNEIDER (USA) INC.,MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DING, NI;HELMUS, MICHAEL N.;SIGNING DATES FROM 19960109 TO 19960118;REEL/FRAME:024552/0778